FDAnews
www.fdanews.com/articles/70913-regenera-in-183-million-deal

Regenera in $183 Million Deal

April 8, 2005

Drug developer Regenera will start receiving royalty income from next year after signing a licensing deal with one of the US's leading ophthalmology companies that is potentially worth up to $US140 million ($183 million). The Perth company has closed months of negotiations by licensing its cortico-steroid drug for use in eye surgery to Alcon Manufacturing, an affiliate of Alcon. The deal gives Alcon an exclusive global licence to manufacture, market and distribute Regenera's drug as a device to give surgeon's more visibility during vitrectomy surgery.

The Sydney Morning Herald (http://www.smh.com.au/news/Business/Regenera-in-183m-deal/2005/04/07/1112815670251.html?oneclick=true)